MRK241108C107000
- 0.01
- 0.000.00%
Merck & Co Newsroom
Argus Cuts Price Target on Merck to $125 From $140
Daiwa Downgrades Merck & Co(MRK.US) to Hold Rating
Daiwa Securities Downgrades Merck to Neutral From Outperform, Adjusts Price Target to $100 From $130
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $130
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $130
Merck Is Maintained at Buy by Truist Securities
Merck & Co Analyst Ratings
Deutsche Bank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $130
Deutsche Bank Cuts Merck Price Target to $140 From $145, Maintains Buy Rating
A Quick Look at Today's Ratings for Merck & Co(MRK.US), With a Forecast Between $120 to $125
Merck Price Target Cut to $110.00/Share From $125.00 by Wells Fargo
Merck Is Maintained at Equal-Weight by Morgan Stanley
Goldman Sachs Adjusts Merck & Co.'s Price Target to $135 From $139
A Quick Look at Today's Ratings for Merck & Co(MRK.US), With a Forecast Between $110 to $150
Merck & Co Analyst Ratings
Merck Is Maintained at Buy by Citigroup
Merck & Co Analyst Ratings
IBRX Soars 47% on Initial Trials For Cell Therapy Product
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140